RHB-104: Interim Phase IIa data

Interim data from the open-label, dose-escalation, Israeli Phase IIa CEASE-MS trial in 18 patients with RRMS showed that twice-daily oral RHB-104 as add-on to Avonex interferon beta-1a led to no “clinically significant” change in

Read the full 349 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE